The Roche-based tPSA risk thresholds for advanced/ aggressive PCa and associated PVs have been estimated in the clinical trial using exclusively tPSA Roche results, as explained in the introduction [13]. These thresholds were specifically estimated for men < and ≥65 years and asymptomatic for ...
Power calculations assessed whether this would be sufficient to detect reductions in prostate cancer mortality of a magnitude likely to be important to the NHS (Gohagan et al, 1994; Auvinen et al, 1996). We considered a range of plausible between-practice coefficients of variation (a measure ...
sensors Article An Ultra-Rapid Biosensory Point-of-Care (POC) Assay for Prostate-Specific Antigen (PSA) Detection in Human Serum Sophie Mavrikou 1 , Georgia Moschopoulou 1,*, Athanasios Zafeirakis 2, Konstantina Kalogeropoulou 2, Georgios Giannakos 2, Athanasios Skevis 1 and Spyridon Kintz...